TrialEuropean journal of clinical investigation2022

Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19.

Francisco Javier Redondo-Calvo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.